首页> Nuclear medicine communications> Gallium-68 prostate-specific membrane antigen PET-CT and the clinical management of prostate cancer.

Gallium-68 prostate-specific membrane antigen PET-CT and the clinical management of prostate cancer.

导出原文传递

翻译打印收藏纠错

第一作者： Tima,Davidson

第一单位： Departments of Nuclear Medicine.;Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

作者： Tima,Davidson ^[1] ; Uri,Amit ^[2] ; Akram,Saad ^[2] ; Maia,Hahiashvili ^[3] ; Elinor,Goshen ^[1] ; Orith,Portnoy ^[4] ; Raanan,Berger ^[5] ; Adam,Goldstein ^[2] ; Igor,Sadetsky ^[2] ; Noam,Weizman ^[2] ; Bar,Chikman ^[6] ; Zohar,Dotan ^[7] ; Yaacov R,Lawrence ^[8] ; Simona,Ben-Haim ^[9] ; Zvi,Symon ^[8] ; Jeff,Goldstein ^[2]

作者单位： Departments of Nuclear Medicine.;Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. ^[1] Radiation Oncology. ^[2] Departments of Nuclear Medicine. ^[3] Radiology.;Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. ^[4] Medical Oncology, Sheba Medical Center, Tel Hashomer. ^[5] Division of Surgery, Assaf Harofeh Medical Center, Zerifin.;Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. ^[6] Department of Urology.;Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. ^[7] Radiation Oncology.;Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. ^[8] Departments of Nuclear Medicine.;Institute of Nuclear Medicine, University College Hospitals, NHS Trust, London, UK. ^[9]